The opening was originally planned for September 9 but was postponed because it coincided with the funeral of King Harald V. Andrew Adamovich, founder of the clinical-stage radiopharmaceutical company AdvanCell, will also attend. He will speak about the growing field of targeted alpha therapy and the importance of reliable isotope supply in bringing these treatments to patients at scale.

Thor Medical produces lead-212 and its precursor isotopes thorium-228 and radium-224 from naturally occurring thorium. The company says its process requires neither irradiation nor nuclear reactors, which gives it cost advantages and minimizes radioactive waste. The ceremony is invitation-only.